Latest Observability News

Magnum Mining has resumed drilling at its Palmares and Azimuth rare earth projects in Brazil, advancing high-grade targets with assay results expected by the end of January.

American Tungsten & Antimony Ltd is set to submit a Notice of Intent for its first diamond drilling program at the Tennessee Mountain Tungsten Project in Nevada, aiming to validate historic high-grade mineralisation and establish a formal resource estimate.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

Terra Metals has announced a significant new discovery of platinum group metal, copper, and nickel sulfide mineralisation at the SW6 target within its Dante Project, signalling a promising expansion of its mineral resource base.

High-Tech Metals Ltd is recommencing a 3,000-metre drilling program at its Wagtail gold deposit in January 2026, aiming to refine resource data and support development studies under a strategic funding agreement.

Global X Management (AUS) Limited has announced final distribution amounts for 28 ETFs listed on the ASX AQUA Market, revealing a varied payout landscape for the period ending 31 December 2025.

Auris Minerals Limited has been queried by the ASX following a sharp rise in its share price and trading volume, with the company denying any undisclosed information behind the surge.

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Vulcan Steel has appointed Gavin Street as its new CEO and managing director, while reshuffling key board roles to maintain a majority of independent directors.

Lion Rock Minerals confirms coarse monazite crystals in residual soils at its Minta Est project, validating its exploration model and advancing its rare-earths ambitions. The milestone achievement also triggers the issuance of 500 million deferred shares to vendors.

Neurizon Therapeutics has progressed its ALS treatment NUZ-001 into critical clinical trial phases, even as the FDA declines its Fast Track Designation request pending more data.

S2 Resources has completed its first drilling campaign at the Warraweena project in NSW, revealing volcanic rocks akin to the Macquarie Arc and promising copper mineralisation. Further geophysical work is planned to pinpoint the source of magnetic anomalies and advance exploration.